Hughes Eric A 4

4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 6, 2026

AI-generated summary of this filing

Updated Mar 6, 2026

TEVA (TEVA) Exec VP Eric A. Hughes Sells 11,277 Shares

What Happened

Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical Officer of TEVA, reported multiple transactions on March 4, 2026. He sold 11,277 ordinary shares in an open-market transaction for total proceeds of $366,102 (weighted average price $32.46). The sale was carried out under a Rule 10b5‑1 trading plan.
The filing also reports conversion/exercise entries of 23,251 derivative units and the grant/award of 50,643 restricted share units (RSUs). One derivative disposal entry shows $0 proceeds, reflecting the non‑cash settlement/conversion of awards rather than a market sale.

Key Details

Transaction date: March 4, 2026.
Open-market sale: 11,277 shares at a weighted average price of $32.46; total reported proceeds $366,102. Price range for the sales: $32.095–$33.30 (per filing).
Derivative activity: 23,251 shares reported as exercised/converted (M) and 23,251 reported as disposed at $0 — this reflects settlement/conversion of derivative awards.
Grant: 50,643 restricted share units (A) reported on March 4, 2026.
Purpose of sale: Footnote states 11,277 shares were sold to cover tax withholding obligations related to RSU vesting.
Plan and rules: Sale executed pursuant to a Rule 10b5‑1 trading plan adopted Nov 10, 2025.
Vesting notes: Prior RSU grant (March 4, 2024) had 23,251 vestings on March 4, 2025 and March 4, 2026, with remaining vesting through 2028; the new RSU grant (Mar 4, 2026) vests in installments 2027–2030 (see footnotes).
Shares owned after transaction: Not specified in the provided excerpt.
Filing timeliness: No late filing flag noted in the provided information.

Context

This filing combines RSU vesting/settlement and a routine tax‑withholding sale. The derivative/award entries indicate conversion or settlement of restricted share units rather than an exercised option followed by a market sale for profit taking.
Sales to cover tax withholding are common when equity awards vest and do not necessarily signal a change in insider sentiment. The 10b5‑1 plan indicates the sale was prearranged.

Form 4

Period: 2026-03-04

See "Remarks"

Transactions

Exercise/Conversion
Ordinary Shares
[F1][F2]
2026-03-04+23,251→ 108,867 total
Sale
Ordinary Shares
[F1][F3][F4][F5]
2026-03-04$32.46/sh−11,277$366,102→ 97,590 total
Exercise/Conversion
Restricted Share Units
[F2][F6][F1]
2026-03-04−23,251→ 46,503 total
→ Ordinary Shares (23,251 underlying)
Award
Restricted Share Units
[F2][F7][F1]
2026-03-04+50,643→ 50,643 total
→ Ordinary Shares (50,643 underlying)

Footnotes (7)

[F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
[F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
[F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
[F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
[F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F6]Restricted share units were granted on March 4, 2024, with 23,251 vested on each of March 4, 2025 and March 4, 2026, 23,251 vesting on March 4, 2027, and 23,252 vesting on March 4, 2028.
[F7]Restricted share units were granted on March 4, 2026, with 12,660 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 12,663 vesting on March 4, 2030.

Signature

/s/ Dov Bergwerk as attorney-in-fact for Eric A. Hughes|2026-03-06

1 file